Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of “Hold” by Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have been assigned a consensus rating of “Hold” from the five brokerages that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $13.75.

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Theravance Biopharma in a report on Tuesday, February 25th.

Theravance Biopharma Trading Down 0.1 %

Shares of TBPH opened at $9.30 on Friday. Theravance Biopharma has a twelve month low of $7.44 and a twelve month high of $10.90. The firm has a market capitalization of $460.08 million, a P/E ratio of -9.21 and a beta of 0.15. The stock’s fifty day simple moving average is $9.37 and its 200 day simple moving average is $9.08.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26). The firm had revenue of $18.75 million during the quarter, compared to analysts’ expectations of $29.90 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. Sell-side analysts predict that Theravance Biopharma will post -1.09 earnings per share for the current year.

Insider Activity

In other news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at approximately $2,786,085. The trade was a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

A number of hedge funds have recently bought and sold shares of TBPH. Aquatic Capital Management LLC purchased a new position in shares of Theravance Biopharma during the 4th quarter valued at approximately $25,000. Quantbot Technologies LP acquired a new stake in Theravance Biopharma in the third quarter valued at $60,000. KLP Kapitalforvaltning AS acquired a new stake in Theravance Biopharma in the fourth quarter valued at $69,000. Teacher Retirement System of Texas bought a new position in Theravance Biopharma during the 4th quarter valued at $103,000. Finally, ClearAlpha Technologies LP acquired a new position in Theravance Biopharma during the 4th quarter worth $109,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.